Inulta SRL, a Romanian consulting firm and software solutions provider, posted RON28.4 million (EUR5.6 million) in 2025, a record high and a 9.6% increase from the RON25.9 million in 2024, according to data submitted to the Finance Ministry.
Antibiotice Iasi (stock symbol: ATB), the largest Romanian owned drug maker, ended the first quarter of 2026 with net profit of RON12.5 million, down 61.5% on the year, amid the contraction of the domestic generic medicines market and fiscal measures applied since the start of 2026, per the company's financial report.